

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appln. No. : 10/529,088 Confirmation No.: 6577
Applicant : Diamandis
Filed : August 4, 2006
TC/A.U. : 1642
Examiner : L. Goddard
Customer No. : 00270
Title : METHODS FOR DETECTING PROSTATE CANCER

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

THIRD INFORMATION DISCLOSURE STATEMENT

Sir:

Applicant submits to the Examiner the attached document listing and this paper pursuant to 37 CFR § 1.56 and § 1.97-1.98. The forms are attached and copies of the documents are enclosed herewith. This Information Disclosure Statement is submitted more than three months from the filing date of this application, but before the receipt of a first Office Action. Therefore, no fees are believed due.

The Director is hereby authorized to charge any deficiency in any fees due with the filing of this paper or credit any overpayment in any fees to our Deposit Account Number 08-3040.

The Examiner is respectfully requested to consider the enclosed documents identified in this paper and in the attached forms during the course of examination of this application.

Respectfully submitted,

HOWSON & HOWSON_{LLP}
Attorneys for Applicants

By: Mary E. Bak
Mary E. Bak
Registration No. 31,215
Suite 210
501 Office Center Drive
Fort Washington, PA 19034
Telephone: 215-540-9200
Telefacsimile: 215-540-5818

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/529,088
				Filing Date	August 4, 2006
				First Named Inventor	Diamandis
				Art Unit	1642
Examiner Name	L. Goddard				
Sheet	1	of	1	Attorney Docket Number	MTS16AUSA

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²	
	AR	BARRY, "Prostate-Specific-Antigen testing for early diagnosis of prostate cancer", N. Engl. J. Med., May 3, 2001, 344(18):1373-1377		
	AS	CATALONA et al., "Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease", JAMA, May 20, 1998, 279(19):1542-1547		
	AT	CATALONA et al., "Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: an alternative model", Urology, August 1999, 54(2):220-224		
	AU	OESTERLING et al., "Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios", J. Urology, September 1995, 154:1090-1095		
	AV	OESTERLING et al., "The use of age-specific reference ranges for serum prostate specific antigen in men 60 years old or older", J. Urology, April 1995, 153:1160-1163		
	AW	OESTERLING, "Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate", J. Urology, May 1991, 145:907-923		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-919 and select option 2.